Cipla Gets 1 USFDA Observation for New York Pharma Plant
Mumbai: Drug major Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has completed a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.
According to the regulatory filing, the USFDA inspection was carried out over a five-day period from July 13, 2026, to July 17, 2026 (EDT). The inspection was conducted as part of the agency’s routine cGMP inspection programme to assess compliance with manufacturing quality standards.
At the conclusion of the inspection, the USFDA issued one inspectional observation to the facility in the form of a Form 483. The company stated that it will work closely with the USFDA and is committed to addressing the observation comprehensively within the stipulated timeline.
Also Read: Cipla Appoints New SMPs as Umang Vohra Steps Down
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.